AMARIN CORP PLC -ADR

AMRN is the ticker symbol for Amarin Corporation, a biopharmaceutical company focused on cardiovascular health. The stock trades on the Nasdaq exchange and represents a small-cap company with a history of commercializing prescription omega-3 products. For current details on AMRN's business and recent developments, refer to the latest data on this page.

Recent performance for AMRN can be found in the price chart and performance metrics displayed on this page. The stock may have experienced significant movements tied to company announcements, prescription trends, or broader market conditions. For the latest performance data, please refer to the current figures shown.

Valuation for AMRN can be assessed using metrics such as price-to-sales, price-to-book, and enterprise value-to-revenue, since the company may not have consistent positive earnings. Comparing these ratios to peers in the biopharmaceutical sector provides context. The current valuation metrics are available on this page.

AMRN may be traded in pre-market and after-hours sessions through certain brokers, though liquidity is often lower and spreads wider. These sessions allow reaction to news outside standard hours, but not all brokers support extended trading. Check with your brokerage for availability and specific hours.

Review AMRN's quarterly and annual financial statements, focusing on revenue trends, gross margins, operating expenses, and net income. Key metrics include prescription volumes, product revenue, and cash burn. Earnings reports and SEC filings provide detailed figures to assess ongoing performance.

Amarin faces risks including regulatory challenges, competition from generic or alternative omega-3 products, intellectual property disputes, and reliance on a limited product portfolio. Additionally, biopharmaceutical stocks are sensitive to clinical trial outcomes, reimbursement decisions, and changes in healthcare policy. These factors can contribute to significant price volatility.